Cite
HARVARD Citation
Cathomas, R. et al. (n.d.). 2500 Orteronel (Ort) maintenance therapy in patients (pts) with metastatic castration resistant prostate cancer (mCRPC) and non-progressive disease after first-line docetaxel (Doc) therapy: Results of a multicenter randomized double-blind placebo-controlled phase III trial (SAKK 08/11). European journal of cancer. 51 (3), pp. S473-. [Online].